Skip to content
TrialScanner

NCT03534453

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Phase 3CompletedAZNLead

Registry record

Lead sponsor
AstraZeneca
Conditions
Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy; Platinum Sensitive
Primary completion
Jan 27, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03534453 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

1 change recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03534453: Olaparib Tablets Maintenance... | TrialScanner